Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Please join us for OncTalk 2022
This is a FREE online event for lung cancer patients, caregivers, and survivors, with the opportunity to interact with several world-class lung cancer oncologists, hear the latest information on treatments and participate in a Q&A session with doctors during this live, virtual event.
The program will be held as an online event on Saturday, December 10, 2022 from 11am-1:30pm Eastern Time, 8am - 10:30am Pacific Time.
This program will be broadcast as a live, online event, and viewers of the Livestream will be able to submit questions online during the program.
If you or someone you know is a lung cancer patient or survivor, don't miss this opportunity to learn from leading oncologists and have the opportunity to ask questions of these experts. There is no fee but seats are limited and registration is recommended.
Join us on December 10!
The Agenda can be found here: https://cancergrace.org/onctalk-2022-agenda
The Faculty Bios can be found here: https://cancergrace.org/onctalk-2022-faculty
And you can Register Here Now!
A huge thank you to our sponsor!
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…